Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 196

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 196
---
 50 mg, and
two received one daily dose of 100 mg, each over four days.

134

Design of the Phase 1b imaging trial of LB-102.

We announced data from our Phase 1b trial in December 2021. We observed that single doses of LB-102
led to a linear, dose-dependent dopamine receptor occupancy that achieved maximal levels at approximately eight hours post-dose and persisted for at least 24 hours, as shown in the figure below. Based on results from our 50 mg single-dose cohort, we
measured dopamine receptor occupancy at 48 hours for the 75 mg single-dose cohort. These results and the previously observed plasma half-life of approximately 12 hours supported our decision to develop LB-102
for once-daily dosing.

For cohorts one, two, and three, single doses of LB-102led to dose-dependent dopamine receptor occupancy.

We evaluated
dopamine receptor occupancy under steady-state conditions in our fourth dose cohort. We observed that the receptor occupancy following the Day 4 dose was relatively consistent over 24 hours in all four volunteers. Under steady-state conditions, at
the 50 mg dose of LB-102, the average receptor occupancy was approximately 70%, and at the 100 mg dose, it was approximately 80%. Previous reports analyzing receptor occupancy of multiple antipsychotic drugs
have found that occupancies of 60% to 80% correlate with maximum efficacy and tolerability in the treatment of schizophrenia. Receptor occupancy above 80% can be associated with an increased risk of EPS.

135

The following chart depicts the dopamine receptor occupancy in the fourth cohort of our
Phase 1b trial.

Dopamine receptor occupancy following repeat dosing of LB-102.S1 and S2 indicate Subject #1 and Subject #2, respectively.

Dopamine receptor occupancy persisted over 24 hours after the final dose of LB-102 was administered under steady-state conditions and yielded a consistent engagement of dopamine receptors not always observed in other antipsychotic drugs.

CompletedPhase 2Trial of LB-102in Acute Schizophrenia Patients

Clinical Trial Design

We conducted a four-week in-patient, double-blind, randomized, placebo-controlled Phase 2 trial of LB-102 for acute schizophrenia patients with total PANSS scores between 80 and 120, who have shown good response to previous antipsychotic drugs other than clozapine in the prior 12 months. The Phase 2 trial
en